MetaCap

PMV Pharmaceuticals (PMVP) vs Zhengye Biotechnology (ZYBT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zhengye Biotechnology (ZYBT) has outperformed PMV Pharmaceuticals (PMVP) over the past year, losing 30.8% versus a loss of 33.6%. Zhengye Biotechnology is the larger company by market cap ($70.1 million vs $66.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PMVP-33.64%ZYBT-30.84%
+292%+102%-87%
Nov 21, 20251 yearNov 20, 2026
PMVP-40.00%ZYBT-67.94%
+206%+53%-100%
Jan 6, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PMVP versus ZYBT key metrics
MetricPMVPZYBT
Share price$0.876$1.48
Market cap$66.17M$70.14M
1-day change-33.13%-2.63%
YTD return-29.92%+28.70%
1-year return-33.64%-30.84%
5-year return-96.22%—
EPS (TTM)$-1.56$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$16.64M
Revenue growth (YoY)—-34.83%
Net income (latest FY)$-77.74M$-9.98M
Gross margin—20.51%
Operating margin—-60.60%
Net margin—-59.99%
52-week high$1.91$8.01
52-week low$0.66$0.616
Distance from 52-week high-54.14%-81.52%
Analyst consensusstrong_buy—
Avg. price target upside+356.62%—
Average volume787.50K569.22K
Shares outstanding75.53M47.39M
Employees54269
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About PMV Pharmaceuticals

PMVP stock →

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees

About Zhengye Biotechnology

ZYBT stock →

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.

Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees

PMVP vs ZYBT FAQ

Which is bigger, PMV Pharmaceuticals or Zhengye Biotechnology?

Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $70.14M compared with $66.17M for PMV Pharmaceuticals (PMVP).

Which stock has performed better over the past year, PMVP or ZYBT?

ZYBT returned -30.84% over the past 12 months, compared with -33.64% for PMVP (price return, excluding dividends). Past performance does not predict future results.

Are PMV Pharmaceuticals and Zhengye Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons